Relaxation of CBD Restriction Sparks Controversy
THC Global Group Limited embraces an interim Therapeutic Goods Administration (TGA) decision to down schedule cannabidiol (CBD) medicines to Schedule 3 to allow easier access of low-dose CBD without prescriptions.
By Judy Ya-Hsuan Lin
THC Global’s Southport Facility is one of the world’s largest pharmaceutical GMP cannabis manufacturing facilities. Because they own Crystal Mountain, a fast-growing hydroponics equipment wholesaler, they can supply wholesalers and retailers in Europe and North America’s rapidly expanding cannabis sector. The CBD market analysis company Brightfield Group predicted that the cannabis industry’s value would hit 22 billion by 2022. Although the down-scheduling ensures a well-documented safety profile, higher accessibility and better affordability to patients, the TGA decision sparks controversy over two parties holding different opinions on the expanding use of CBD.
The THC decision to expand CBD legalizes many activities and conveniences in daily life, but limited clinical evidence demonstrates the extent of therapeutic effectiveness and safety for individuals and patients. Thus, the decision poses potential suspicion. Zsolt Csonka, the founder of Adriaen Block restaurant located in Astoria, New York, uses CBD-contained concomitants in his dishes to optimize customers’ tasting experience.
Besides, he shared his experience that it usually takes 4-5 shots of Whiskey for people to feel relaxed but only two shots containing CBD to impose the same effect. Dr. Chris Freeman, the Pharmaceutical Society of Australia national president, told the Australian Journal of Pharmacy an opposing opinion. He is concerned about the lack of clinical evidence of low-dose CBD’s therapeutic efficacy for patients and the current absence of enough information to ensure patients access these medicines appropriately.
©www.geneonline.com All rights reserved. Collaborate with us: email@example.com